SubscribeAlmac and Rosetta Biosoftware announced this week that Almac has licensed the Rosetta Resolver® system for use in the development of novel microarray-based approaches for diagnosing cancer and predicting therapeutic outcomes.
The Resolver system will also be used in the provision of comprehensive gene expression analysis services offered by Almac Diagnostics to academic, biotech and pharmaceutical customers. Chief Executive of Almac Diagnostics, Professor Paul Harkin commented, "At Almac Diagnostics, we are dedicated to promoting discovery.
Almac Diagnostics is pioneering a novel transcriptomics-based approach to develop tools, which will radically improve diagnosis and treatment of cancer. The Resolver system provides the comprehensive solution necessary for us to advance this type of research and realize more targeted and personalized approaches for cancer diagnosis and prognosis.
"Furthermore, our use of the Resolver system will allow all our service customers to benefit from state-of-the-art technology in gene expression data management, analysis and visualization." "We are pleased to continue to expand our business by supporting cancer diagnostic research," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.
"The Resolver system provides a flexible platform to enable researchers to use microarray data in a large biological context, such as the development of disease-specific microarrays for diagnosing cancer."
About Almac Diagnostics and Almac SciencesAlmac Diagnostics -- a division of the Almac Sciences Group -- develops, markets and supplies, leading-edge genomic expression services and products.Almac Diagnostics has two divisions:The Genomic Services business provides all inclusive gene expression and bioinformatic services to academia, biotech and pharmaceutical companies.
These services include analysis on our unique disease specific arrays, which provide the ability to detect the maximum information in a given cancer type. Almac Diagnostics is the first Authorised Affymetrix Service Provider to successfully gain accreditation to ISO17025 for our comprehensive Gene Expression Microarray and Bioinformatics services.
The Research & Development Division develops, using proprietary arrays, new tests that will change the way cancers are managed in the future. These proprietary arrays provide unique information for individual cancer types and represent a stable, long-term platform for the development of clinical diagnostics.www.almac-diagnostics.comAlmac Sciences is a global, knowledge-based leader in the research, development and delivery of pharmaceutical services.
Its services, provided by affiliated companies -- CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and Almac Diagnostics -- extend through all phases of drug discovery and clinical trials to the commercialisation of pharmaceutical product. US operations are based in Pennsylvania, North Carolina and California.
European operations are headquartered in Craigavon, Northern Ireland, with additional operations in London and Edinburgh. www.almac-sciences.com
For further information please contact:
Matthew Dixon
Stakeholder Communications
020 7903 5149
Matthew.dixon@stakeholdergroup.com